The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
Gilead Sciences GILD
Clears the common standard
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
read at $129.31
Gilead Sciences holds its Distribution at $129.31.
- PHPhase · the trend structure carries the Distribution label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · does not pass the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the buyers, held for 1 days |
| Price | $129.31 |
| Valuation | 17.59 trailing · 13.43 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.34 |
The opportunity · what the numbers say it is worth
Our framework reads AVOID — it trades at roughly a 39% discount to our $180.00 fair value, strong competitive moat, 4.40% revenue growth.
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Revenue growth | 4.40% |
| Profit margin | 30.99% |
| Debt to equity | 94.64 |
| Analyst consensus | Buy · 27 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✗ DOES NOT PASS
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is 42.2% of its assets, above the one-third ceiling the screen allows. Against market value it is 13.8%, under the 30% line the market-value standard uses — so that standard clears it. Divergent
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 5.0% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 21.1% of assets, under the 49% limit. Pass
- Revenue purity Only 1.2% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Gilead's Debt Load Fails Our Ethical Screen
Patients in clinics from Atlanta to Berlin take Gilead medicines daily to manage HIV and hepatitis. The company turns those needs into steady cash with a 31% profit margin and 43% return on equity, backed by a strong moat in antivirals.
Yet the numbers do not clear our bar. Revenue growth sits at just 4% and the business fails the ethical screen on its debt ratio, even though the shares trade at 13.8 times forward earnings with a margin of safety to our 180 dollar fair value.
High leverage leaves the firm exposed when patents roll off or rates stay elevated. Analysts may still favour the name, but we pass. Analysis, not advice.
| Forward P/E | 13.4x expensive even after accounting for its growth |
| Trailing P/E | 17.6x reasonably valued |
| Revenue growth | 4.4% slow but positive growth |
| Profit margin | 31.0% highly profitable on every dollar of sales |
| Return on equity | 43.4% an exceptional return on shareholder capital |
| Debt to equity | 0.95 moderate, manageable leverage |
| Current ratio | 1.97 healthy short-term liquidity |
| Beta | 0.34 barely tracks the market's swings |
| Market cap | $160.5B |
| Employees | 17,000 |
The risks · The things to watch: as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Latest news · what the market is reading on GILD
- › Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? Trefis · 1d ago
- › 2 Large-Cap Stocks for Long-Term Investors and 1 Facing Challenges StockStory · 2d ago
- › Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics Zacks · 3d ago
- › Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? Zacks · 3d ago
- › Do Wall Street Analysts Like Gilead Sciences Stock? Barchart · 3d ago
Headlines from third-party outlets, linked for reference — not our reporting, not advice.
Related securities · others in GILD's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
GILD trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The insider ledger · Form 4 filings, as filed
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-15 | MERCIER JOHANNA | Officer | 25,000 | $1,666,000 | |
| 2026-05-15 | MERCIER JOHANNA | Officer | 28,000 | $3,676,199 | |
| 2026-05-15 | DICKINSON ANDREW D | Chief Financial Officer | 3,000 | $396,810 | |
| 2026-04-30 | RODRIGUEZ JAVIER | Director | 1,146 | · | |
| 2026-04-30 | HORNING SANDRA | Director | 1,146 | · | |
| 2026-04-30 | LOVE TED WENDELL | Director | 1,146 | · | |
| 2026-04-30 | BLUESTONE JEFFREY | Director | 1,146 | · | |
| 2026-04-30 | MANWANI HARISH | Director | 1,146 | · | |
| 2026-04-30 | BARTON JACQUELINE K | Director | 1,146 | · | |
| 2026-04-30 | WELTERS ANTHONY | Director | 1,146 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
The political ledger · congressional disclosures
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 6 May2026 | Jared Moskowitz | Democrat | buy | 1K–15K |
| 2026-04-13 | Ro Khanna | Democrat | Sale | 15K–50K |
| 15 May2026 | Ro Khanna | Democrat | buy | 15K–50K |
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $133.52 | -8.7% | · | $913 | -8.7% |
| 2 months | $138.99 | -12.3% | · | $877 | -12.3% |
| 3 months | $144.39 | -15.6% | $0.82 | $850 | -15.0% |
| 6 months | $121.71 | +0.1% | $1.61 | $1,014 | +1.4% |
| 1 year | $107.24 | +13.6% | $3.19 | $1,166 | +16.6% |
| 2 years | $61.26 | +98.9% | $6.29 | $2,092 | +109.2% |
| 3 years | $70.57 | +72.7% | $9.31 | $1,859 | +85.9% |
| 5 years | $57.08 | +113.5% | $15.11 | $2,399 | +139.9% |
Historical returns from market close data. Past performance does not guarantee future results.